Fetal hemoglobin grabs oxygen more tightly than adult hemoglobin largely because it resists the molecule that would otherwise weaken its grip. Inside red blood cells, a small compound called 2,3-bisphosphoglycerate (2,3-BPG) binds to hemoglobin and lowers its oxygen affinity. Fetal hemoglobin’s gamma chains have a different amino acid composition from adult hemoglobin’s beta chains, and that difference sharply reduces how well 2,3-BPG can latch on. The result is a hemoglobin that holds onto oxygen at lower oxygen pressures, which is exactly what a fetus needs to pull oxygen across the placenta from its mother’s blood.
What Happens at the Molecular Level
Adult hemoglobin (HbA) is built from two alpha chains and two beta chains. Fetal hemoglobin (HbF) swaps those beta chains for gamma chains. The two chain types are similar but not identical, and a handful of amino acid differences in the gamma chain change how the whole molecule behaves. The most consequential change involves a stretch called the A-helix near the beginning of the chain. Studies using hybrid hemoglobins, where researchers mix and match segments of adult and fetal chains, have pinpointed this region as a major source of fetal hemoglobin’s increased oxygen affinity.1PubMed Central. Embryonic and Fetal Human Hemoglobins: Structures, Oxygen Binding, and Physiological Roles
The key player is 2,3-BPG, a small negatively charged molecule produced naturally inside red blood cells. In adult hemoglobin, 2,3-BPG slips into a pocket between the two beta chains and stabilizes the “tense” or low-affinity form of the molecule, making it easier to release oxygen in the tissues. Fetal hemoglobin’s gamma chains have amino acid substitutions that make this pocket less hospitable to 2,3-BPG. Research using engineered hemoglobin variants has shown that the difference between proline at position 5 in adult beta chains and glutamic acid at that same position in fetal gamma chains is especially critical for reducing 2,3-BPG binding, even though that residue does not directly contact 2,3-BPG in the adult molecule.2PubMed Central. Amino acids responsible for decreased 2,3-biphosphoglycerate binding to fetal hemoglobin Without 2,3-BPG pulling it into the low-affinity state, fetal hemoglobin stays in a higher-affinity configuration and binds oxygen more readily.
Why the Fetus Needs That Extra Affinity
A fetus lives in what physiologists describe as a low-oxygen environment.3Comprehensive Physiology. Placental Gas Exchange and the Oxygen Supply to the Fetus It cannot breathe, so every molecule of oxygen it uses has to cross from the mother’s blood into the fetal blood through the placenta. The oxygen pressure on the fetal side of the placenta is much lower than what you would find in your lungs. If fetal blood used adult hemoglobin with its ordinary affinity, it would struggle to load enough oxygen under those conditions.
The affinity difference creates a kind of tug-of-war that the fetus wins. When maternal blood and fetal blood flow past each other in the placenta, maternal hemoglobin releases oxygen (because the local oxygen pressure is lower than in the lungs), and fetal hemoglobin scoops it up (because its higher affinity lets it bind oxygen even at those low pressures). MRI-based studies in animal models have confirmed this by measuring what is called the P50, the oxygen pressure at which hemoglobin is half-saturated. The P50 in fetal liver was significantly lower than in maternal liver, by about 21% at mid-gestation and about 41% near term.4PubMed Central. MR Imaging-derived Oxygen-Hemoglobin Dissociation Curves and Fetal-Placental Oxygen-Hemoglobin Affinities A lower P50 means the hemoglobin grabs oxygen at lower pressures, which is precisely the advantage fetal hemoglobin provides.
The Stripped-Condition Paradox
Here is something that surprises people who dig into the research: when you remove 2,3-BPG entirely and measure fetal and adult hemoglobin in pure solution at moderate temperature, fetal hemoglobin actually shows a lower oxygen affinity than adult hemoglobin.5PubMed. Physiological relevance of the overall delta H of oxygen binding to fetal human hemoglobin This means the intrinsic affinity of fetal hemoglobin, the affinity baked into its protein structure alone, is not higher. It only becomes higher inside a red blood cell, where 2,3-BPG is present and can exert its effect on adult hemoglobin far more than on fetal hemoglobin.
This distinction matters because it tells you the real story is not that fetal hemoglobin was “designed” to be stickier for oxygen. It was shaped to be less responsive to 2,3-BPG. The net effect in the body is the same: fetal blood picks up oxygen more easily. But the mechanism is indirect. Rather than strengthening the oxygen-binding site itself, evolution tweaked how the molecule responds to its chemical environment.
The picture is different in some other species. In fetal bovine hemoglobin, for instance, the oxygen affinity is considerably higher than the adult version even in stripped (cofactor-free) conditions.6PubMed. Oxygen transport by fetal bovine hemoglobin And in at least one viviparous fish species, the fetal-maternal affinity difference comes entirely from intrinsic hemoglobin properties rather than differences in cofactor concentrations.7The Journal of experimental biology. Specific fetal hemoglobin underlies the fetal-maternal difference in blood O2 affinity in a viviparous teleost Mammals as a group use at least three distinct strategies to ensure fetal blood has higher oxygen affinity than maternal blood.8Blood. Evolution of Mammalian Hemoglobin Function Humans happen to rely heavily on the 2,3-BPG mechanism, but nature has found other solutions to the same problem.
Cooperativity and the Bohr Effect
Oxygen affinity is only part of what makes hemoglobin effective. Hemoglobin also needs to be cooperative: once one oxygen molecule binds, the remaining binding sites should become progressively easier to fill, and vice versa for unloading. Both fetal and adult hemoglobin are cooperative, and theoretical analysis shows that the degree of cooperativity in both forms is close to optimal for making the Bohr effect work well. The Bohr effect is the phenomenon where lower pH (more acidic conditions, as in active tissues) causes hemoglobin to release oxygen more readily. Modeling suggests that the cooperativity seen in real hemoglobin hits a sweet spot: high enough to make the Bohr effect efficient at the oxygen pressures where it matters, but not so high that it would actually reduce the Bohr shift’s effectiveness.9Zoological Science. The Cooperativity of Human Fetal and Adult Hemoglobins is Optimized: A Consideration Based on the Effectiveness of the Bohr Shift
For the fetus, this means oxygen delivery is not just about binding more tightly. The Bohr effect helps fetal hemoglobin release oxygen in fetal tissues, where metabolic waste products lower the pH. The placenta itself also contributes: fetal blood picks up carbon dioxide waste and carries it to the placenta, where it crosses into maternal blood. That exchange shifts the pH balance in a direction that further promotes oxygen transfer from mother to fetus. The whole system is coordinated, not just a matter of one hemoglobin being “stickier.”
Hemoglobins Even Before Fetal Hemoglobin
Before fetal hemoglobin takes over, the very early embryo produces its own set of hemoglobins. In the first weeks of development, when the embryo is tiny and getting oxygen by simple diffusion from surrounding tissue, it makes hemoglobins called Gower-1, Gower-2, and Portland. These use different combinations of embryonic globin chains (zeta and epsilon) alongside or instead of the alpha and beta/gamma chains found later.
The oxygen-binding properties of these embryonic hemoglobins are distinctive. Gower-1, built entirely from embryonic subunits, has an elevated P50 (meaning lower affinity), a reduced Bohr effect, and increased 2,3-BPG binding compared to adult hemoglobin. Gower-2, which pairs adult-type alpha chains with embryonic epsilon chains, behaves more similarly to adult hemoglobin in its oxygen-binding properties.10PubMed. Expression, purification, and characterization of human hemoglobins Gower-1 (zeta(2)epsilon(2)), Gower-2 (alpha(2)epsilon(2)), and Portland-2 (zeta(2)beta(2)) assembled in complex transgenic-knockout mice Gower-2’s higher affinity compared to adult hemoglobin appears to come from a reduced chloride effect rather than 2,3-BPG interactions, a mechanistically different route to a similar outcome.11Journal of Molecular Biology. Crystal structure of a human embryonic haemoglobin: the carbonmonoxy form of Gower II (α2ϵ2) haemoglobin at 2.9 Å resolution
These embryonic hemoglobins are normally produced only during the first eight weeks or so of gestation, then silenced as fetal hemoglobin takes over. The succession from embryonic to fetal to adult hemoglobin is a tightly regulated developmental program, with each hemoglobin type suited to the oxygen delivery needs of its stage.
The Switch to Adult Hemoglobin After Birth
Once a baby is born and starts breathing, fetal hemoglobin’s higher affinity goes from being an advantage to being unnecessary and even slightly counterproductive. Higher affinity means tighter holding, which can make it harder to release oxygen into tissues now that the lungs are supplying plenty. The body addresses this by switching off the genes for gamma globin and ramping up beta globin production.
At birth, fetal hemoglobin makes up roughly 60 to 80 percent of total hemoglobin. One study found it as high as 98% at birth.12PubMed Central. Fetal hemoglobin during infancy and in sickle cell adults Detailed measurements of hemoglobin synthesis in normal full-term infants show a rapid decline in fetal hemoglobin production during the first months of life, reaching low levels (around 3%) by 16 to 20 weeks of age. The complete transition follows a sigmoid curve centered on the period between the 30th and 52nd postconceptional week.13Journal of Clinical Investigation. The postnatal decline of hemoglobin F synthesis in normal full-term infants By the time a child is about a year old, nearly all their hemoglobin is the adult type.
How the Genes Get Switched Off
The molecular machinery behind the fetal-to-adult hemoglobin switch has been a major area of research, partly because understanding it could open doors to treating blood diseases. The key repressor is a protein called BCL11A. In adult red blood cell precursors, BCL11A binds directly to the promoters of the gamma-globin genes and silences them. It does this by competing with an activator protein called NF-Y for a binding site on the gamma-globin promoter. BCL11A essentially elbows NF-Y out of the way through physical obstruction, preventing the genes from being turned on.14PubMed Central. Transcription factor competition at the γ-globin promoters controls hemoglobin switching
BCL11A does not work alone. It recruits protein complexes that modify the DNA packaging around the gamma-globin genes, making them physically less accessible. One such partner is the LSD1/CoREST complex, which removes chemical marks from histone proteins that would otherwise keep the genes in an “open” and active state.15PubMed Central. Corepressor-dependent silencing of fetal hemoglobin expression by BCL11A A second, independent repressor called LRF (also known as ZBTB7A) works through a different complex (NuRD) to maintain dense nucleosome packing at the gamma-globin genes, adding another layer of silencing.16PubMed Central. Transcription factors LRF and BCL11A independently repress expression of fetal hemoglobin The fact that two independent repressors converge on the same genes underscores how committed the adult body is to keeping fetal hemoglobin off.
When the Switch Never Fully Happens
Some people continue producing meaningful amounts of fetal hemoglobin throughout their lives due to a condition called hereditary persistence of fetal hemoglobin (HPFH). This is a benign genetic condition in which the normal shutoff of gamma-globin gene expression is incomplete.17PubMed Central. Hereditary persistence of fetal hemoglobin HPFH can arise from deletions in the beta-globin gene cluster or from point mutations in the gamma-globin promoter regions that disrupt the binding sites for repressors like BCL11A. People with HPFH have normal red blood cell counts, no anemia, and typically no symptoms. The condition is often discovered incidentally during unrelated blood tests.18Indian Journal of Medical Biochemistry. Hereditary Persistence of Fetal Hemoglobin: A Benign Condition Causing Diagnostic Challenges in Hemoglobin Variants—A Case Report
HPFH is medically interesting for two reasons. First, it can cause confusion during hemoglobin testing. Elevated fetal hemoglobin can mimic or mask the patterns seen in thalassemia or other hemoglobin disorders, leading to unnecessary worry or follow-up testing. Second, HPFH is actually protective in people who also carry genes for sickle cell disease or beta-thalassemia. Fetal hemoglobin does not participate in the sickling process because it does not polymerize the way sickle hemoglobin does. People with sickle cell disease who also have HPFH tend to have milder symptoms, which is one of the observations that sparked interest in reactivating fetal hemoglobin therapeutically.
Fetal Hemoglobin as a Therapeutic Target
The protective effect of fetal hemoglobin in sickle cell disease has made it one of the most actively pursued therapeutic targets in hematology. The drug hydroxyurea, which has been used for decades, works in part by boosting fetal hemoglobin levels in adults. But newer approaches aim to reactivate fetal hemoglobin more directly and durably by editing the genes involved in the hemoglobin switch.
Clinical trials have tested gene editing strategies that target the BCL11A enhancer, a regulatory region that controls BCL11A production specifically in red blood cell precursors. By disrupting this enhancer with CRISPR-based tools, researchers can reduce BCL11A levels and allow gamma-globin genes to turn back on. Early results in patients with sickle cell disease and beta-thalassemia have shown relief from disease symptoms, though the long-term durability of the effect remains uncertain.19Molecular Therapy. Genome Editing Strategies for Fetal Hemoglobin Induction The FDA approved the first CRISPR-based therapy for sickle cell disease (exagamglogene autotemcel, marketed as Casgevy) in late 2023, a milestone that traces directly back to decades of research on the fetal hemoglobin switch.
Researchers have also explored whether modified versions of fetal hemoglobin could be even more effective than the natural form at preventing sickle hemoglobin from polymerizing. Experiments with recombinant fetal hemoglobin carrying single amino acid substitutions at position 43 in the gamma chain showed that several mutants were substantially better than natural fetal hemoglobin at keeping sickle hemoglobin in solution.20PubMed. Enhanced inhibition of polymerization of sickle cell hemoglobin in the presence of recombinant mutants of human fetal hemoglobin with substitutions at position 43 in the gamma-chain That work is still in the laboratory stage, but it illustrates how understanding fetal hemoglobin’s structure opens the door to engineering proteins with specific therapeutic goals.
Fetal Hemoglobin in Blood Substitute Research
Beyond sickle cell disease, fetal hemoglobin’s properties have attracted interest from researchers trying to develop hemoglobin-based oxygen carriers, sometimes loosely called artificial blood. One challenge with using free hemoglobin outside of red blood cells is that it tends to break down and cause toxicity. Researchers typically attach chemical groups like polyethylene glycol (PEG) to stabilize the protein, but this can impair its function and adds cost.
One group has explored attaching a polypeptide tag called XTEN to a fusion form of fetal hemoglobin as an alternative to PEGylation. The XTEN-tagged fetal hemoglobin retained its functional properties, including oxygen affinity and spectral characteristics, while potentially avoiding the drawbacks of chemical modification.21Lund University Publications. Towards New Generation of Hemoglobin-Based Blood Substitutes Fetal hemoglobin’s naturally higher affinity in whole blood conditions could be an advantage or a disadvantage for a blood substitute depending on the application. In situations where you need oxygen delivery to very low-oxygen tissues, the higher affinity could be beneficial. In other contexts, adult hemoglobin’s willingness to release oxygen more readily might be preferable. The field is still far from a clinically practical product, but fetal hemoglobin’s unique binding properties keep it in the conversation.
Why This Question Gets Oversimplified
Textbook explanations of fetal hemoglobin’s higher affinity often condense the story to a single sentence: “fetal hemoglobin does not bind 2,3-BPG as well as adult hemoglobin.” That is correct as far as it goes, but it glosses over several layers of complexity. The intrinsic affinity reversal in stripped conditions means the gamma chain is not inherently a better oxygen binder. The reduced 2,3-BPG binding itself comes not from a single amino acid swap at the binding site but from structural effects propagated through the A-helix region, involving residues that do not even directly touch 2,3-BPG. The Bohr effect, cooperativity, and pH changes at the placenta all contribute to the overall efficiency of oxygen transfer. And the developmental program that produces fetal hemoglobin at the right time and shuts it off after birth involves multiple independent gene silencing mechanisms with redundant safeguards.
The oversimplification also misses the broader evolutionary picture. Different mammals have solved the fetal oxygen problem in different ways. Some species rely on differences in 2,3-BPG sensitivity like humans do. Others have fetal hemoglobins with genuinely higher intrinsic affinity. Still others manipulate the concentrations of organic phosphates in fetal versus maternal red blood cells rather than changing the hemoglobin itself. The fact that multiple independent evolutionary solutions exist for the same problem says something about how fundamental it is: any live-bearing animal needs to get oxygen to its offspring before birth, and hemoglobin is the dial that nature has turned repeatedly.